← Back to headlines
Anbogen Therapeutics and University of Tokyo Collaborate on ABT-301 Research
Anbogen Therapeutics and The University of Tokyo have entered a collaborative research agreement to evaluate ABT-301 across multiple tumor types, aiming to accelerate human clinical indication expansion.
24 Aug, 00:23 — 24 Aug, 00:23
